| payload |
{"created_at":"2026-04-05T00:39:30.733 {"created_at":"2026-04-05T00:39:30.733352+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:d0e3f197aaf2098c","evidence_event_ids":["evt_2b253b2cf098"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/immunomes-chief-scientist-trimmed-his-stake-planned-fda-submission-tells-you-more","as_of":"2026-04-05T00:39:30.733352+00:00","canonical_url":"https://www.fool.com/coverage/filings/2026/04/04/immunome-s-chief-scientist-trimmed-his-stake-a-planned-fda-submission-tells-you-more/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/immunomes-chief-scientist-trimmed-his-stake-planned-fda-submission-tells-you-more","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_1bb3705da958b2f5","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/coverage/filings/2026/04/04/immunome-s-chief-scientist-trimmed-his-stake-a-planned-fda-submission-tells-you-more/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-05T02:06:02.662694+00:00","extraction_method":"heuristic","fetched_description":"Key Points9,438 shares were sold for a transaction value of ~$204,000 on April 2, 2026.","fetched_title":"Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More | Nasdaq","final_url":"https://www.nasdaq.com/articles/immunomes-chief-scientist-trimmed-his-stake-planned-fda-submission-tells-you-more","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/immunomes-chief-scientist-trimmed-his-stake-planned-fda-submission-tells-you-more","source_event_id":"evt_2b253b2cf098","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"860709f8fb742629","kind":"unusual_volume","published_at":"2026-04-04T23:25:46+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["2026-04-02"],"entities":[{"asset_class":"equity","name":"Immunome","relevance":"high","symbol":"IMNM","type":"company"}],"event_type":"other","information_gaps":["No baseline volume data provided for unusual volume analysis.","No confirmation of news directly related to the volume change."],"key_facts":["9,438 shares sold for ~$204,000 on April 2, 2026","Sale represented 30.02% of Higgins\u2019s holdings","Post-sale direct holding of 22,000 shares"],"numeric_claims":[{"label":"shares sold","value":"9438"},{"label":"transaction value","value":"$204,000"},{"label":"percentage of holdings sold","value":"30.02%"}],"primary_claim":"Jack Higgins sold 9,438 shares of Immunome (NASDAQ: IMNM) on April 2, 2026, for approximately $204,000.","relevance_score":0.8,"sentiment":"neutral","source_quality":"high","summary":"Immunome's Chief Scientist, Jack Higgins, sold 9,438 shares on April 2, 2026, representing 30.02% of his holdings, as part of a pre-arranged trading plan, while a planned FDA submission for a drug is a key catalyst.","topics":["insider trading","FDA submission","biotechnology"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key Points9,438 shares were sold for a transaction value of ~$204,000 on April 2, 2026.","tickers":[],"title":"Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More","url":"https://www.fool.com/coverage/filings/2026/04/04/immunome-s-chief-scientist-trimmed-his-stake-a-planned-fda-submission-tells-you-more/"}}... |